Press release
Lewy Body Dementia Treatment Market 2034 - Market Size, Competitive Landscape, Clinical Trials, Market Dynamics, Epidemiology, Companies | DelveInsight
Lewy Body Dementia Treatment Market
DelveInsight's report, "Lewy Body Dementia Market Insights, Epidemiology, and Market Forecast-2034," provides a detailed evaluation of LBD, encompassing historical and forecasted epidemiology, current and emerging therapeutic landscape, market share trends, and projected market size across the US, EU4, the UK, and Japan. The analysis highlights treatment algorithms, clinical practices, key market drivers and barriers, unmet needs, and future opportunities in the LBD domain.
To Know in detail about the Lewy Body Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lewy Body Dementia Market Forecast - https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Lewy Body Dementia Market Highlights
• The Lewy Body Dementia market was valued at ~USD 670 million in 2022, expected to grow significantly from 2020-2034.
• June 2025: CervoMed strengthened its development and commercialization strategy for neflamapimod with key leadership appointments.
• July 2025: NKGen Biotech received FDA Expanded Access Program authorization for troculeucel, extending its use to multiple neurodegenerative diseases, including LBD.
• June 2025: Cognition Therapeutics scheduled an end-of-Phase 2 meeting with the FDA to discuss Phase 2 SHINE trial results and the Phase 3 program for zervimesine (CT1812).
• March 2025: Positive interim results from the Phase 2b RewinD-LB extension study of neflamapimod were announced.
• January 2025: C2N Diagnostics partnered with MJFF to advance research into neurodegenerative proteinopathies, including LBD.
• January 2025: Topline data from the SHIMMER study of CT1812 in DLB were presented at ILBDC.
• December 2024: Exploratory Phase 2 SHIMMER results showed significant behavioral, cognitive, and motor improvements with CT1812.
• In 2022, there were 21.4 million prevalent dementia cases in the 7MM, with 12.6 million diagnosed.
• 720,478 individuals in the 7MM were diagnosed with DLB in 2022, projected to rise steadily through 2034.
• The US accounted for 42% of diagnosed DLB cases, with substantial CAGR expected going forward.
• Male prevalence exceeded female prevalence in the US, consistent with global patterns.
• The UK reported the highest DLB prevalence among EU countries in 2022, followed by Germany; Spain recorded the lowest.
• Key Lewy Body Dementia Companies: Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics, Cephalon, Athira Pharma, Ortho-McNeil Neurologics, Inc., H. Lundbeck A/S, Axovant Sciences Ltd., GE Healthcare, Aptinyx, NeuroActiva, Inc., CuraSen Therapeutics, Inc., ACADIA Pharmaceuticals Inc., and others
• Key Lewy Body Dementia Therapies: E2027, Neflamapimod, K0706, RVT-101, CT1812, K0706, Irsenontrine, Donepezil, ATH-1017, Galantamine, Memantine, Nelotanserin, DatSCAN, NYX-458, N-831(Traneurocin), CST-103, CST-107, Pimavanserin, and others
• The Lewy Body Dementia epidemiology based on gender analyzed that through various secondary studies it can be found that LBD more commonly affects males than females
• The Lewy Body Dementia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lewy Body Dementia pipeline products will significantly revolutionize the Lewy Body Dementia market dynamics.
Unlock comprehensive insights into the evolving Lewy Body Dementia market - explore epidemiology trends, key players, emerging therapies, and growth opportunities with DelveInsight's in-depth report : Lewy Body Dementia Treatment Market - https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Lewy Body Dementia Overview
Lewy Body Dementia is a progressive neurodegenerative condition characterized by the accumulation of α-synuclein (Lewy bodies) in the brain. It accounts for 10-15% of all dementia cases and presents with cognitive decline, Parkinsonian motor features, visual hallucinations, REM sleep behavior disorder, and fluctuating cognition. Due to overlapping symptoms with Alzheimer's and Parkinson's disease, misdiagnosis is common. Although no curative therapies exist, symptomatic management through cholinesterase inhibitors, cautious antipsychotic use, and supportive therapies remains the standard. Current research efforts aim to develop disease-modifying treatments.
Lewy Body Dementia Epidemiology Insights
In 2022, the 7MM recorded nearly 21 million dementia cases, with ~52% diagnosed. The US had the largest diagnosed population (~5 million dementia cases), with ~300,000 cases attributed to LBD. Japan followed with ~130,000 diagnosed LBD cases, whereas the UK reported ~44,000. Prevalence was higher in males, and highest among individuals aged 85+. Prevalence across the 7MM is expected to continue rising through 2034 due to aging populations and improved detection.
Lewy Body Dementia Epidemiological segmentation includes:
• Overall Lewy Body Dementia prevalence
• Severity-based prevalence
• Gender distribution
• Diagnosed episodic vs. chronic Lewy Body Dementia cases
Download the report to understand which factors are driving Lewy Body Dementia epidemiology trends @ Lewy Body Dementia Prevalence- https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Lewy Body Dementia Drug Uptake & Pipeline Landscape
Rising healthcare investment and active pipeline development by companies such as Cognition Therapeutics, EIP Pharma, Athira Pharma, Eisai, and Eli Lilly are expected to reshape the LBD treatment landscape.
• E2027: Eisai
• Neflamapimod: EIP Pharma
• K0706: Sun Pharma
• RVT-101: Axovant Sciences Ltd.
• CT1812: Cognition Therapeutics
• K0706: Cephalon
• Irsenontrine: Eisai Inc.
• Neflamapimod: EIP Pharma Inc
• Donepezil: Eisai Co., Ltd.
• ATH-1017: Athira Pharma
• Galantamine: Ortho-McNeil Neurologics, Inc.
• Memantine: H. Lundbeck A/S
• Nelotanserin: Axovant Sciences Ltd.
• DatSCAN: GE Healthcare
• NYX-458: Aptinyx
• N-831(Traneurocin): NeuroActiva, Inc.
• CST-103, CST-107: CuraSen Therapeutics, Inc.
• Pimavanserin: ACADIA Pharmaceuticals Inc.
Discover how pipeline therapies like Neflamapimod (EIP Pharma) and CT1812 (Cognition Therapeutics), along with innovations from key players such as Eisai, Sun Pharma, Axovant, and ACADIA, are shaping the future of Lewy Body Dementia treatment. Access DelveInsight's in-depth market report for strategic insights @ Lewy Body Dementia Medication and Companies - https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Lewy Body Dementia Market Drivers
• Growing prevalence of dementia and aging populations
• Improvements in diagnostics and biomarker technologies
• Advancing pipeline of targeted therapies
• Supportive government and research initiatives
• Increased industry collaboration
Lewy Body Dementia Market Barriers
• Absence of approved disease-modifying therapies
• High attrition rates in neurodegenerative drug trials
• Diagnostic overlap with other neurological disorders
• High cost of emerging therapies
• Limited awareness in developing markets
Lewy Body Dementia Market Report Scope
• Study duration: 2020-2034
• Geography: 7MM - US, EU4, UK, Japan
• Assessment: Market size, epidemiology, pipeline, treatment landscape, reimbursement, unmet needs, and competitive intelligence (SWOT, PESTLE, Porter's Five Forces, BCG Matrix).
To know more about Lewy Body Dementia companies working in the treatment market, visit @ Lewy Body Dementia Clinical Trials and Therapeutic Assessment - https://www.delveinsight.com/sample-request/lewy-body-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lewy Body Dementia Treatment Market 2034 - Market Size, Competitive Landscape, Clinical Trials, Market Dynamics, Epidemiology, Companies | DelveInsight here
News-ID: 4276743 • Views: …
More Releases from DelveInsight Business Research
Bronchitis Treatment Market 2034: Market Size, Competitive Landscape, Companies, …
The bronchitis therapeutics market is projected to grow steadily from 2025-2034, driven by rising disease prevalence, technological progress, and the emergence of new treatment options. Current management focuses on symptom relief through bronchodilators, corticosteroids, and antibiotics for acute cases, while chronic bronchitis requires long-term inhaled therapies, pulmonary rehabilitation, and lifestyle changes. A key advancement is the FDA-approved OHTUVAYRE (ensifentrine), which offers dual bronchodilator and anti-inflammatory benefits. Despite progress, there is…
Asthma Market is projected to grow at a CAGR of 1.9% During 2024-2034, Estimates …
DelveInsight's "Asthma Market Insights, Epidemiology, and Market Forecast - 2034" report offers a comprehensive analysis of asthma, including historical and projected epidemiology, along with market trends across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Explore detailed insights into the evolving Asthma Market here: Asthma Market Size - https://www.delveinsight.com/report-store/asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Highlights from the Asthma Market Report
• February 2025 - Areteia Therapeutics: Ongoing study evaluating the efficacy and…
Global Endovascular Aneurysm Repair Devices Market Size to grow at a CAGR of 5.8 …
According to DelveInsight's analysis, the increasing prevalence of abdominal and thoracic aortic aneurysms (AAA and TAA) is a major driver of the Endovascular Aneurysm Repair (EVAR) market. With a growing aging population, there is rising demand for minimally invasive treatments like EVAR, which offer benefits such as shorter hospital stays, fewer complications, and faster recovery compared to traditional surgery. Moreover, ongoing technological advancements in EVAR devices such as more flexible…
Global Cardiac Mapping System Market Size to grow at a CAGR of 8.37% by 2032, Ev …
According to DelveInsight's analysis, The growing prevalence of cardiac arrhythmias, including atrial fibrillation and ventricular tachycardia, is driving the expansion of the cardiac mapping system market. These systems are crucial for early diagnosis and treatment, providing real-time visualization of the heart's electrical activity to prevent serious complications such as stroke and heart failure. Moreover, the increasing adoption of minimally invasive procedures like catheter ablation, which rely heavily on advanced mapping…
More Releases for Lewy
Lewy Body Dementia Treatment Market Trends That Will Shape the Next Decade: Insi …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Lewy Body Dementia Treatment Market Size By 2025?
The market for lewy body dementia therapies has experienced robust expansion lately, projected to increase its valuation from $4.43 billion in 2024 to $4.69 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.8%; this…
Lewy Body Dementia Market to Reach USD 9.4 Billion by 2034
Lewy Body Dementia (LBD) is the second most common form of progressive dementia after Alzheimer's disease, accounting for 10-15% of dementia cases. It is caused by the abnormal accumulation of alpha-synuclein protein (Lewy bodies) in the brain, leading to cognitive decline, visual hallucinations, fluctuating alertness, REM sleep behavior disorder, and Parkinsonism symptoms.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71909
With aging populations and rising awareness, the LBD market is…
Lewy Body Dementia Market Forecast 2025-2034: Comprehensive Analysis And Growth …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Is the Projected Growth of the Lewy Body Dementia Market?
In recent times, the market size for Lewy body dementia has witnessed substantial growth. It is projected to increase from $1.12 billion in 2024 to $1.21 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. The historic growth…
Lewy Body Disease Pipeline: 10+ Innovators Advancing Disease-Modifying and Sympt …
Lewy Body Disease (LBD), including dementia with Lewy bodies and Parkinson's disease dementia, is a complex neurodegenerative condition attracting the attention of over 10 key companies such as Cognition Therapeutics, Eli Lilly and Company, Athira Pharma, and NLS Pharmaceutics. The LBD pipeline features therapies targeting alpha-synuclein, neuroprotective agents, and symptomatic treatments that address cognition, motor symptoms, and neuropsychiatric complications. With no approved disease-modifying treatment, this pipeline represents a vital frontier…
Lewy Body Dementia Treatment Market Challenges: Growth, Share, Value, Trends and …
Lewy Body Dementia Treatment Market Size And Forecast by 2031
The LBD Therapy Market is expanding rapidly, driven by increasing consumer demand, technological advancements, and industry-wide innovation. According to top market research firms, businesses in the Neurodegenerative Disorder Treatment Market are prioritizing digital transformation, product development, and data-driven decision-making to stay competitive. With rising investments in automation and efficiency, the Dementia Care Market is evolving to meet changing customer preferences.…
Lewy Body Dementia Treatment Market Focuses on Advancements in Diagnosis and The …
Global Lewy Body Dementia Treatment Market, By Drug Type (Cholinesterase Inhibitors, Antipsychotic Drugs, Antidepressants, Benzodiazepine, and Modafinil), Application Type (Parkinson's Disease and Alzheimer's Disease), Mode of Purchase (Prescription and Over the Counter), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies and Others) - Industry Trends and Forecast to 2031.
Data Bridge Market Research analyses that the Global Lewy Body Dementia Treatment Market which was USD 5.66 Billion in 2023…
